# Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)

> **NCT07625332** · PHASE2,PHASE3 · RECRUITING · sponsor: **Northwell Health** · enrollment: 60 (estimated)

## Conditions studied

- Spinal Cord Injury
- Traumatic Spinal Cord Injury
- Paraplegia and Tetraplegia
- Metabolic Syndrome

## Interventions

- **DRUG:** Galantamine Hydrobromide Extended Release

## Key facts

- **NCT ID:** NCT07625332
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625332, "Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07625332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*